Two key studies from ACR/ARP 2020 shed new light on our use of IL-6 inhibitors, including tocilizumab and sarilumab.
Two key studies from ACR/ARP 2020 shed new light on the best approach to tapering therapy during RA remission.
New studies from ACR/ARP 2020 add to our understanding of cardiovascular safety with several RA therapeutics and demonstrate effectiveness of herpes zoster vaccination in patients with RA.
When is a rheumatoid really a rheumatoid, and what are the implications for telemedicine?
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.